Meeting | Mixed
Event Title
FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds
August 25, 2026
- Date:
- August 25, 2026
- Time:
- 10:00 a.m. - 4:30 p.m. ET
- Location:
-
Event LocationFDA White Oak Campus
Building 31, Conference Center, The Great Room (Room 1503)
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
United States
On August 25, 2026, the U.S. Food and Drug Administration (FDA) hosted a hybrid public meeting on Patient-Focused Drug Development for Nonhealing Chronic Wounds. This meeting provided FDA and other key stakeholders, including medical product developers, health care providers, and academic researchers, the opportunity to hear directly from patients, patient representatives, and care partners about their experiences with nonhealing chronic wounds, including how the wounds and associated wound care affect their daily life, what matters most to them, their current approaches for managing or treating their nonhealing chronic wounds, and what they consider when determining whether to participate in a clinical trial.
There were three sessions focused on: (1) health effects and daily impacts, (2) current approaches to treatment, and (3) perspectives on clinical trials. Each topic began with a brief initial patient panel discussion followed by a facilitated discussion inviting comments from other patient and care partner participants in the audience.
The meeting recording can be found here.
Public Docket
We encourage participants to submit written comments to the public docket by October 26, 2026: https://www.regulations.gov/document/FDA-2026-N-5057-0001 or visit www.regulations.gov and search for FDA-2026-N-5057.
Related Information
CDER Patient-Focused Drug Development